Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: A dose-ranging study

European Journal of Neurology

Volumn 5, Issue 5, 1998, Pages 469-477

  Dahlöf, Carl ^a   Hogenhuis, Leon ^b   Olesen, Jes ^c   Petit, Henri ^d   Ribbat, Jacques ^e   Schoenen, Jean ^f   Boswell, Diane ^g   Fuseau, Eliane ^g   Hassani, Habib ^g   Winter, Paul ^g  

^a Migrankliniken   (Sweden)

^b Reinaert Kliniek   (Netherlands)

^c KAS Glostrup   (Denmark)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e DRK Schmerz Zentrum   (Germany)

^f Centre Hospitalier Regional de La Citadelle   (Belgium)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Acute treatment; Migraine; Naratriptan; Placebo; Subcutaneous; Sumatriptan

Indexed keywords

ANTIMIGRAINE AGENT; NARATRIPTAN; SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; VERTIGO; VOMITING;

EID: 15644378539     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.1998.550469.x     Document Type: Article

References (13)

1. Connor HE, O'Shaughnessy CT, Fenuik W, Perren MJ, North PC, Oxford AW, et al. (1993). GR85548: a potent selective agonist for the intracranial vascular 5-HT1 receptor. Br J Pharmacol 108 (proc suppl):99P.
2. Ferrari MD (1997). 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists. Neurology 48 (suppl 3):S21-S24.
3. Fuseau E, Baille P, Kempsford RD (1997). A study to determine the absolute oral bioavailability of naratriptan. Cephalalgia 17(3):07-A15.
4. Headache Classification Committee of the International Headache Society (1988). Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8:1-96.
5. Kempsford RD, Lacey LF, Keene ON, Thomas M (1993). The safety, tolerability and pharmacokinetics of subcutaneous GR85548, a novel 5-HT1 receptor agonist for the treatment of migraine. Br J Clin Pharmacol 36: 17P.
6. Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A (1997). Naratriptan is effective and well-tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group. Headache 37(10):640-645.
7. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A (1997). Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 49(6):1485-1490.
8. McCullagh P, Neider JA (1983). Generalised linear models. London: Chapman and Hall. pp. 101-126.
9. Pilgrim AJ, Blakeborough P (1994). The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemporary Pharmacotherapy 5(4):295-309.
10. Plosker GL, McTavish D (1994). Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 47:622-651.
11. Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M (1997). Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 49(5):1225-1230.
12. Simmons VE, Blakeborough P (1994). The safety profile of sumatriptan. Rev Contemporary Pharmacotherapy 5(4): 319-328.
13. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD (1996). Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol 53(11):1132-1137.